Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | PACIFIC: Brentuximab vedotin in mediastinal DLBCL

Jason Westin • 12 Dec 2021
ASH 2021
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Brentuximab vedotin
PACIFIC

Jason Westin, MD, FACP, University of Texas MD Anderson Center, Houston, TX, describes the trial design of the Phase II PACIFIC trial (NCT04745949) of brentuximab vedotin, an antibody-drug conjugate (ADC), in patients with stage I-IV primary mediastinal diffuse large B-cell lymphoma (DLBCL). The trial aims to evaluate immunotherapy in the frontline setting as an alternative to chemotherapy in patients with mediastinal DLBCL, which will reduce the toxicity experienced by patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Jason Westin

Expanding the CAR platform in NHL
David Maloney et al. • 17 Oct 2023
1:41
Real-world efficacy of tafasitamab + lenalidomide in R/R DLBCL & the importance of patient selection
Jason Westin • 8 Sep 2023
2:05
Clinical guidance for the use of bispecific antibodies in NHL
Jason Westin • 8 Sep 2023
2:08
The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & more
Jason Westin • 8 Sep 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals